Domenico Tricò
Domenico Tricò, MD, PhD is an expert in Endocrinology at University of Pisa (Italy). As of October 2026, ScienceLeadR ranks Domenico Tricò in the top 1% of experts worldwide for Glucose Metabolism Disorders and Diabetes Mellitus. Domenico Tricò has authored 166 publications, the most recent in 2026, and is an investigator in 11 clinical trials, 2 of them ongoing. SLR score: 652 (community average: 125). How the SLR is computed.
LeadR Profile
Endocrinology
Subspecialties: Public Health - Cardiology - Biochemistry
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2013 - 2026
Number : 166
Citations
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Global Burden of Anorexia Nervosa and Bulimia Nervosa, 1990 to 2023, With Forecasts to 2050: A Global Burden of Disease Study 2023 Analysis. PMID 42949727 — bulimia nervosa, anorexia, mortality, bulimia, mental disorders, global burden of disease, prevalence, cost of illness, anorexia nervosa, mental health | JAMA Psychiatry | 2026 | 0 |
| Global, regional, and national burden of unintentional poisoning, 1990-2023: results from the Global Burden of Disease Study 2023. PMID 42945982 — incidence, poisoning, public health, uncertainty, pesticides, global burden of disease, cost of illness, demography | Lancet Public Health | 2026 | 0 |
| Global, regional, and national burden of tuberculosis and multidrug-resistant tuberculosis by HIV status, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023. PMID 42385762 — fasting, mortality, tuberculosis, multidrug-resistant, incidence, global health, pharmaceutical preparations, global burden of disease, hiv, tuberculosis, risk factors, morbidity, cost of illness, smoking, communicable diseases, plasma | Lancet Infect Dis Top journal | 2026 | 2 |
| Global, Regional, and National Burden of Heart Failure, 1990-2023: A Systematic Analysis for the Global Burden of Disease Study 2023. PMID 42814432 — heart diseases, heart failure, heart, cardiovascular diseases, public health, global burden of disease, prevalence, cost of illness, chagas disease | JAMA Cardiol | 2026 | 0 |
| Clinical Evidence of Kidney Protection Exerted by SGLT2 Inhibitors. PMID 42778649 — kidney diseases, sodium-glucose transporter 2 inhibitors, albuminuria, kidney, pharmacology, therapeutics | Handb Exp Pharmacol | 2026 | 0 |
Clinical Studies 11
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
2 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Deciphering the Role of Incretin Hormones in Weight Loss induced Remission of Type 2 Diabetes (DIABeat) NCT06333132 — diabetes mellitus, pharmaceutical preparations, hormones, body weight, obesity, incretins, weight loss, diabetes mellitus, type 2 | N/A | Not yet recruiting | 2024 |
| Sodium Glucose Cotransporter 2 Inhibitors and Salt sensitivity in Type 2 Diabetes NCT06007157 — diabetes mellitus, sodium-glucose transport proteins, blood, hypersensitivity, blood pressure, body composition, diet, diet, sodium-restricted, diabetes mellitus, type 2 | N/A | Recruiting | 2023 |
LeadR Networks
Main global connection map